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Abstract
Background: Our previous work and that of others strongly suggests a relationship between the infiltrative phenotype of
gliomas and the expression of MMP-2. Radiation therapy, which represents one of the mainstays of glioma treatment, is
known to increase cell invasion by inducing MMP-2. Thus, inhibition of MMP-2 provides a potential means for improving the
efficacy of radiotherapy for malignant glioma.
Methodology/Principal Findings: We have tested the ability of a plasmid vector-mediated MMP-2 siRNA (p-MMP-2) to
modulate ionizing radiation-induced invasive phenotype in the human glioma cell lines U251 and U87. Cells that were
transfected with p-MMP-2 with and without radiation showed a marked reduction of MMP-2 compared to controls and pSV-
transfected cells. A significant reduction of proliferation, migration, invasion and angiogenesis of cells transfected with p-
MMP-2 and in combination with radiation was observed compared to controls. Western blot analysis revealed that
radiation-enhanced levels of VEGF, VEGFR-2, pVEGFR-2, p-FAK, and p-p38 were inhibited with p-MMP-2-transfected cells.
TUNEL staining showed that radiation did not induce apoptosis in U87 and U251 cells while a significant increase in TUNEL-
positive cells was observed when irradiated cells were simultaneously transfected with p-MMP-2 as compared to controls.
Intracranial tumor growth was predominantly inhibited in the animals treated with p-MMP-2 alone or in combination with
radiation compared to controls.
Conclusion/Significance: MMP-2 inhibition, mediated by p-MMP-2 and in combination with radiation, significantly reduced
tumor cell migration, invasion, angiogenesis and tumor growth by modulating several important downstream signaling
molecules and directing cells towards apoptosis. Taken together, our results demonstrate the efficacy of p-MMP-2 in
inhibiting radiation-enhanced tumor invasion and progression and suggest that it may act as a potent adjuvant for
radiotherapy in glioma patients.
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Introduction
Patients with glioblastoma multiforme (GBM), the most
common type of human primary brain tumor and the most lethal
of all human tumors, have a median survival of less than one year
[1–3]. Despite advances in neurosurgery, radiation therapy, and
chemotherapy, this prognosis has not changed significantly over
the past two decades. Contributing to the deadly nature of the
disease is the ability of glioblastoma cells to extensively invade
normal brain tissue, thereby preventing a surgical cure and
resistance of glioblastoma to existing therapeutic modalities,
including radiotherapy [1]. Excessive proliferation, disseminated
tumor growth, resistance to apoptotic stimuli, neovascularization,
and suppression of anti-tumor immune surveillance are key
biological features that contribute to the malignant phenotype of
gliomas [4,5]. Tumor cells obtain these invasive properties
primarily because of their ability to secrete and activate proteolytic
enzymes, such as serine, metallo, and cysteine proteases, which are
capable of degrading extracellular matrix (ECM) components and
breaking down other natural barriers to tumor invasion [6,7].
Matrix metalloproteinases (MMPs) are zinc-dependent, proteo-
lytic endopeptidases involved in cancer progression. Elevated
levels of MMPs, in particular increased expression and activity of
MMP-2 (72-kDa gelatinase A) and MMP-9 (92-kDa gelatinase B),
have been correlated with an increased grade of glioma
malignancy [8–10]. MMP-2 is highly expressed in gliomas as
compared to normal brain tissue, and multiple roles have been
indicated for this molecule in tumor progression. MMP-2 activates
several key molecules leading to rapid cellular proliferation,
increased motility, invasion, and angiogenesis of gliomas. Growth
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angiogenic factors, chemokines, and cytokines are some of the
diverse substrates targeted by MMPs [9,11].
Oneofthemajorlimitationsinthe treatmentofglioma isthehigh
prevalence of acquired resistance to radiation, which is likely
associated with intrinsic cellular radioresistance, rapid cellular
proliferation, and high invasiveness [12,13]. Because radiation
therapy continues to be the mainstay of cancer treatment, tumor
resistance to ionizing radiation has been extensively studied. Of
major interest is the role of MMPs in changing tumor cell properties
and inducing an invasive phenotype after ionizing radiation [13–
16]. Ionizing radiation induces an increase in MMP-2 levels in
almost all human cancer types [17–23]. Radiation-enhanced
expression as well as activation of the MMP-2 proteolytic system
elevate or modify the bioavailability of several molecules that
promote tumor progression. Enhanced MMP-2 secretion may
increase tumor survival by decreasing apoptosis, stimulating
proliferation, and increasing angiogenic and invasive potential. All
these factors may contribute to the high vascularity as well as the
high radioresistance of GBM [13–16].
There is strong biological background for the development of
strategies targeting MMP-2. Nevertheless, several MMP inhibitors
have proved to be disappointing in clinical trials due to either lack of
benefits or major adverse effects [24]. Today, RNA interference-
based, targeted silencing of gene expression is a strategy of potential
interest for cancer therapy [25,26]. Further, the specificity and
potency of siRNA-MMP-2 in cell culture and in animal studies
suggests that it has the potential to be a powerful therapeutic agent
[27–29]. Viral vectors, particularly adenoviral ones, have been the
primary gene transfer vehicle of choice. However, two concerns are
the ability of adenoviral proteins to trigger an immune response and
the limited length of time that the gene expression can be maintained
in the target cells. Plasmid-based vectors have been considered to be
more safe and efficient [30].
Since radiation is standard treatment for patients with GBM and
because radiation-induced changes in invasive phenotype of glioma
have been shown to be possiblydue to changes in MMP activation, in
t h ep r e s e n ts t u d y ,w eh a v et e s t e dt h ea b i l i t yo fap l a s m i dv e c t o r -
mediated MMP-2 siRNA to modulate the ionizing radiation-induced
invasive phenotype in human glioma cell lines, U-251 and U-87. We
also investigated the anti-tumor effects of combining MMP-2
inhibition using the plasmid vector-mediated MMP-2 siRNA with
radiation therapy in vivo. Our study shows that MMP-2 inhibition,
mediated by plasmid DNA, in combination with radiotherapy
reduces cell proliferation, tumor cell migration, invasiveness, and
angiogenesis. We also show that inhibition of radiation-enhanced
MMP-2 modulated important downstream signaling molecules,
thereby directing the cells towards an apoptotic phenotype.
Results
p-MMP-2 transfection inhibits radiation-enhanced MMP-
2 expression and cell viability
To examine the effect of radiation on MMP-2 expression, we
determined MMP-2 activity in U-251 and U-87 cells irradiated with
various X-ray doses. Radiation-induced MMP-2 activity increased up
to10GyforU-251andupto8GyforU-87anddecreasedthereafter.
The decreased levels of MMP-2 activity beyond 10 and 8 Gy for the
two cell lines could be due to severe damage of DNA and other
proteins. Maximal induction in pro-MMP-2 activity (72 kDa) was
observed at 8 and 10 Gy when compared to the control, 0 Gy
(Fig. 1A). Since MMPs play a role in the induction of malignant
phenotype, we used a plasmid vector carrying siRNA against MMP-2
(p-MMP-2) to inhibit MMP-2 expression. We first determined the
concentration of the plasmid DNA, which would give maximum
inhibition of MMP-2 activity and levels when U-251 and U-87 cells
were transfected. Figure 1B demonstrates that pro-MMP-2 activity
was minimal when cells were transfected with 2 mgo ft h ep l a s m i d
DNA. The figure shows a dose-dependent decrease in cellular MMP-
2 levels with little or no MMP-2 detected when cells were transfected
with 2 mg of the plasmid DNA. We therefore used this concentration
(2 mg) of the plasmid DNA carrying MMP-2 siRNA or the scrambled
sequence in combination with various doses of radiation for all
experiments in the study. Western blots of cell lysates showed
unchanged levels of MMP-9 when compared to the internal control
GAPDH, thereby demonstrating the specificity of p-MMP-2. We
next determined the effect of p-MMP-2 on radiation-induced MMP-
2e x p r e s s i o n .F i g u r e s2 Aa n dBs h o wp r o - M M P - 2a c t i v i t yl e v e l sa n d
protein levels, and mRNA levels of U-251 and U-87 transfected with
p-MMP-2 or p-SV alone or in combination with various doses of
radiation. Cells that were transfected with p-MMP-2 without
radiation showed a significant decrease in activity/levels of MMP-2
when compared to the mock or p-SV controls or when compared to
cells subjected to irradiation alone. The combination of p-MMP-2
and radiation caused a further decrease in MMP-2 levels. Maximal
inhibition was observed with 6 Gy followed by 4 Gy. We further
confirmed these results by immunofluorescence staining of the cells,
which revealed similar results. There was a marked reduction in
MMP-2 staining in all irradiated and concomitantly transfected cells,
as well as in cells treated with p-MMP-2 alone (Fig. 2C). Cell
viability/proliferation, as measured by MTT assay, was significantly
reduced when U-251 and U-87 cells were concomitantly transfected
with p-MMP-2 and irradiated or when cells were treated with p-
MMP-2 alone when compared to the controls (Fig. 2D).
p-MMP-2 inhibits radiation-enhanced glioma cell
migration and invasion
Since MMP-2 has been implicated as an important factor in
malignant glioma cell migration and invasion into the surrounding
normal tissue, which is a major problem for any therapeutic
modality, we studied the effect of p-MMP-2 on these processes.
Since tumor spheroids mimic tumor growth, we allowed U-87 or U-
251 cells to form spheroids, and then transfected and irradiated the
cells. We observed a significant reduction in the migrating potency
of cells transfected with p-MMP-2 and of cells that were
concomitantly transfected and irradiated as compared to the
controls. Cell migration was decreased five-fold and even more
(particularly with 4 and 6 Gy) in the p-MMP-2 transfected and
irradiated cells when compared to controls (Fig. 3). Matrigel
invasion assay showed a significant inhibition of invasion by tumor
cells that were transfected with p-MMP-2 without exposure to
radiation and an even more significant dose-dependent inhibition
when cells were concomitantly transfected and irradiated at various
doses. Maximal inhibition was observed with 4 Gy followed by 6
Gy. Inhibition was significant when compared to mock or p-SV-
transfected controls or to cells that were only subject to radiation.
The normalization of the values as a percentage of the control
(100%) cells treated with p-MMP-2 and concomitantly irradiated (6
Gy) showed a more than 90% inhibition (Fig. 4).
p-MMP-2 inhibits tumor-induced and radiation-enhanced
angiogenesis in vitro and decreases expression of
angiogenesis-associated molecules
We next determined the ability of p-MMP-2 to inhibit
angiogenesis. Glioblastoma is one of the most highly angiogenic
tumors; MMP-2 is an important angiogenic molecule that promotes
tumor vascularization, in turn rendering the tumor cells resistant to
Inhibition of Glioma Invasion
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combination with radiation treated U-87 or U-251 cells failed to
induce capillary-like formation when added to cultured human
microvascular endothelial cells (HMECs) in contrast to conditioned
media obtained from control and p-SV transfected cells, which was
capable of triggering the angiogenic process. Mock and p-SV treated
cells that were subject to radiation demonstrated enhanced
angiogenesis, as is evident from the increase in percentage of
branching when compared to their non-irradiated counterparts
(Fig. 5A). Western blot analyses revealed enhanced levels of vascular
endothelial growth factor (VEGF), a well-known inducer of
angiogenesis, VEGF receptor-2 (VEGFR-2), and also a correspond-
ing increase in phosphorylation of VEGFR-2 in lysates of irradiated
glioma cells. p-MMP-2 treatment markedly reduced radiation-
enhanced protein levels, which were almost completely inhibited
when cells were simultaneously treated with the MMP-2 inhibitor
and irradiated at 4 or 6 Gy (Fig. 5B). We also demonstrated the effect
of radiation and the combined treatment on p38 and FAK, which are
downstream molecules of VEGF signaling. Radiation-enhanced
levels of phosphorylated p38 and phosphorylated FAK were largely
inhibited when cells were simultaneously transfected with p-MMP-2.
Levels of total p38 and FAK remained unchanged for the different
Figure 1. Radiation enhances MMP-2 and p-MMP-2 inhibits MMP-2 activity and expression in glioma cell lines. A, U-251 and U-87 cells
were irradiated with 0–12 Gy X-ray, incubated for 24 h, and conditioned medium collected. MMP-2 activity was determined by gelatin zymography.
The band intensities of MMP-2 activity were quantified by densitometry. Columns: mean of triplicate experiments; bars: SD; *p,0.01, **p,0.001,
significant difference from non-irradiated (0 Gy) conditioned medium. B, U-251 and U-87 cells were transfected with mock (PBS), p-SV or p-MMP-2
(1, 2 or 3 mg). After 72 h of incubation, conditioned media was used to determine MMP-2 activity by gelatin zymography, and total cell lysates were
used to determine MMP-2 and MMP-9 levels by Western blotting. The band intensities of MMP-2 activity as well as MMP-2 and MMP-9 protein levels
were quantified by densitometry and normalized with the intensity of the mock bands. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served
as a loading control. Columns: mean of triplicate experiments; bars: SD; *p,0.01, **p,0.001, significant difference from mock or p-SV.
doi:10.1371/journal.pone.0020614.g001
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(Fig. 5B).
p-MMP-2 inhibits colony formation and induces
apoptotic cell death in irradiated glioma cells
We performed the colony forming assay to determine the effect of
p-MMP-2 and radiation on the survival of glioma cells. Treatment
with p-MMP-2 followed by irradiation as well as treatment with p-
MMP-2 alone significantly reduced clonogenic survival when
compared to the irradiated cells (Fig. 6A). High levels of MMP-2 in
gliomas and radiation-enhanced MMP-2 are known to render tumor
cells less susceptible to apoptosis. TUNEL staining showed that
radiation did not induce apoptosis in the glioma cells while a
significant increase in TUNEL-positive cells was observed when
Figure 2. p-MMP-2 transfection inhibits radiation-enhanced MMP-2 activity and expression levels as well as cell viability. A, U-251
and U-87 cells were transfected with mock (PBS), p-SV or p-MMP-2 (2 mg), and after 72 h of incubation, cells were irradiated with 0, 2, 4, 6 or 8 Gy and
incubated for a further 24 h. Conditioned media was used to determine MMP-2 activity by gelatin zymography, and total cell lysates were used to
determine MMP-2 levels by Western blotting. B, Total RNA was used to determine MMP-2 mRNA transcription levels by RT-PCR with gene-specific
primers. GAPDH served as a loading control. C, U-251 and U-87 cells were transfected with mock, p-SV or p-MMP-2 and irradiated as described above.
24 h after radiation, the cells were fixed and processed to visualize MMP-2 expression. The cells were mounted using mounting media with DAPI to
visualize the nucleus. D, U-251 and U-87 cells were transfected with mock, p-SV or p-MMP-2, and irradiated for 72 h after transfection. After a another
24 h of incubation, cell viability was analyzed by MTT assay (absorbance read at 550 nm). Columns: mean of triplicate experiments; bars: SD; *p,0.01,
significant difference from mock, p-SV or irradiated controls.
doi:10.1371/journal.pone.0020614.g002
Inhibition of Glioma Invasion
PLoS ONE | www.plosone.org 4 June 2011 | Volume 6 | Issue 6 | e20614irradiated cells were simultaneously transfected with p-MMP-2 as
compared to the controls. Quantification revealed up to 80%
induction of apoptosis in cells treated with the MMP-2 siRNA
construct and irradiated at 6 Gy (Fig. 6B). Moreover, caspases 3, 8
and 9, which mediate the apoptotic mechanism, were cleaved and
activated in irradiated cells transfected with p-MMP-2 as shown by
comparison of Western blot analysis of cell lysates from the different
treatment groups (Fig. 6C).
p-MMP-2 combined with radiation inhibits tumor growth
in vivo
For the intracerebral injections, we chose the glioblastoma cell
line U-251, which forms highly invasive tumors in athymic mice in
contrast with U-87 cells that form solid and well defined tumors.
Ten days after tumors were induced, animals were treated on
alternate days for a total of 4 doses with 60 mg per dose of p-SV or
pMMP-2 or phosphate-buffered saline (mock). Mice were injected
with stably transfected U-251 cells expressing a luciferase plasmid,
which enabled us to monitor tumor growth by intraperitoneally
injecting D-luciferin into the animals. Over a 6-week period,
tumor growth was predominantly inhibited in the animals treated
with p-MMP-2 alone or in combination with radiation when
compared with the mock or p-SV controls as observed in the IVIS
images and subsequently confirmed by hematoxylin and eosin
(H&E) staining of the tumor sections (Figs. 7A–B). Control animals
developed symptoms of weight loss and neurological degradation
before they were euthanized, whereas animals treated with p-
MMP-2 alone or concomitantly irradiated remained symptom-
free. No significant differences were observed between animals
treated with mock or p-SV in terms of tumor size or symptoms.
Brain sections were analyzed for expression of MMP-2 by
immunohistochemistry (Fig. 8A). Mice treated with p-MMP-2
alone or in combination with radiotherapy showed a decrease in
MMP-2 expression. Conversely, in control and p-SV treated mice
or even mice that were subject to only radiation in which MMP-2
expression was detected mostly at the invasive edge of the tumor
and in cells surrounding the necrotic areas as well as reactive
endothelial cells within and around the tumor area. Confirming
the in vitro findings, VEGF and pFAK were also suppressed in the
animals treated with MMP-2 siRNA alone or in combination with
radiation (Fig. 8A). TUNEL staining of tissue sections showed that
radiation did not induce apoptosis in the glioma cells while
predominant TUNEL staining was observed in tissues of mice that
were treated with p-MMP-2 alone and in those that were
concomitantly irradiated (Fig. 8B). Further, we noticed that the
invasiveness of the tumor cells into adjacent normal brain tissue of
mice increased with radiation compared to mock and pSV
controls, but decreased in mice that received p-MMP-2 alone or in
combination of radiation (Fig. 8C). Further, tumor infiltrating cells
were detected in non-tumor regions of brain sections from mice
Figure 3. p-MMP-2 transfection in combination with radiation inhibits glioma cell migration. U-251 and U-87 cells were cultured for
formation of spheroids as described in Materials and Methods. Spheroids were then transfected with mock, p-SV or p-MMP-2, and followed by
irradiation as described earlier. At the end of the migration assay, spheroids were fixed and stained with Hema-3. Migration of cells from spheroids to
monolayers was measured using a microscope calibrated with a stage and ocular micrometer. Columns: mean of triplicate experiments; bars: SD;
*p,0.01, **p,0.001, significant difference from mock, p-SV or irradiated controls.
doi:10.1371/journal.pone.0020614.g003
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identification of human cells (a specific human nuclear antigen). A
considerable number of tumor infiltrating cells were observed in
tumor sections from mice that received mock and pSV treatments.
In addition, we observed a significant increase in the number of
tumor infiltrating cells in tumor sections from mice that received
radiation treatment. However, we observed a drastic reduction in
radiation-induced tumor cell infiltration in tumor sections from
mice that received pMMP-2 (Fig. 8D). The immunoreactivity of
MMP-2 in tumor sections from mice that received both radiation
and p-MMP-2 treatments also showed that p-MMP-2 inhibited
radiation-induced MMP-2 expression. These results suggest that
p-MMP-2 could serve as an adjuvant with low-dose radiation
therapy against glioblastoma.
Discussion
Findings of the present study demonstrate the anti-tumor efficacy
of combining a plasmid vector-mediated MMP-2 inhibitor (p-
MMP-2) with ionizing radiation to target radiation-induced
invasiveness and angiogenesis in glioma cells. Our results show
that p-MMP-2 significantly inhibited radiation-enhanced MMP-2
protein expression and activity and its associated tumorigenic
properties, such as cell proliferation, tumor cell migration, invasion,
and angiogenesis in two human glioma cell lines, U-251 and U-87.
We also show that the decrease in MMP-2 expression/activity
further modulated important downstream signaling molecules
directing the cells towards an apoptotic phenotype when adminis-
tered in combination with radiotherapy.
MMP-2 activation has been associated with invasive phenotype in
glioma cells [31–33]. In our experiments, the MMP-2 inhibitor, p-
MMP-2, significantly downregulated MMP-2 protein expression and
activity and modulated multiple biological behaviors that determine
the malignant progression of gliomas. Previous reports show that
ionizing radiation increased MMP-2 activity and protein secretion
along with invasiveness of glioma cells [15]. We observed that
ionizing radiation induced a dose-dependent increase in MMP-2
activity in U-251 and U-87 cells. As demonstrated by Wick, et al.,
[34] we also observed that irradiation promoted the accumulation of
MT1-MMPand lossof TIMP-2 protein, possiblyshifting the balance
of these molecules in favor of MMP-2. Treatment of cells with p-
MMP-2 and in combination with irradiation seemed to show a slight,
though not significant, decrease in levels of MT1-MMP and more or
less unchanged levels of TIMP-2 when compared to irradiated
cellular protein levels (data not shown). This was of interest as the
activation and regulation of MMP-2 is closely associated with MT1-
MMP and TIMP-2. Given the specificity of our p-MMP-2 siRNA
and its ability to significantly downregulate radiation-enhanced
invasiveness, angiogenesis, and cell survival, it is very evident that
MMP-2 might be associated with the exceeding invasiveness after
radiation. Several studies have shown that MMP-2 and MMP-9
promote cancer progression by increasing tumor cell growth,
Figure 4. p-MMP-2 transfection inhibits radiation-enhanced glioma cell invasion. U-251 and U-87 cells were transfected with mock, p-SV
or p-MMP-2, and irradiated as described earlier. Cells were trypsinized and counted, and 5610
5 cells from each treatment condition were allowed to
invade transwell inserts containing 12-mm-pore polycarbonate membranes pre-coated with Matrigel for 24 h at 37uC. Afterwards, cells were fixed and
stained with Hema-3. Cells that had migrated to the lower side of the membrane were photographed under a light microscope at 206magnification.
Percentages of invading cells were quantified by counting five fields from each treatment condition. Columns: mean of triplicate experiments; bars:
SD; *p,0.01, **p,0.001, significant difference from mock or irradiated controls.
doi:10.1371/journal.pone.0020614.g004
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Thus, following radiation, it is logical that the elevated levels of
MMP-2 and a subsequent increase in activation of the MMP-2
proteolytic system would only lead to enhanced invasiveness. MMPs
exert these effects by cleaving a diverse group of substrates, which
include not only structural components of the extracellular matrix,
but also growth factor binding proteins, growth factor precursors,
receptor tyrosine kinases, cell adhesion molecules, and other
proteinases [9]. There was a marked increase in VEGF and
VEGFR-2 secretion and an increase in phosphorylated VEGFR-2
Figure 5. p-MMP-2 inhibits radiation-enhanced tumor culture medium-induced microtubule network formation in endothelial cells
and downregulates expression of angiogenesis-associated molecules. A, Human microvascular endothelial cells (5610
4) were seeded in 96-
well plates and cultured with conditioned medium collected from U-251 and U-87 glioma cells transfected with mock, p-SV, and p-MMP-2, and
irradiated as described earlier. 24 h after radiation treatment, the cells were washed, fixed and stained with Hema-3 and photographed. Percentages
of branches were quantified by counting five fields in each condition. Columns: mean of triplicate experiments; bars: SD; *p,0.01, **p,0.001,
significant difference from mock or irradiated controls. B, U-251 and U-87 transfection and radiation was carried out as described earlier. 24 h after
radiation, whole cell lysates were prepared and analyzed by Western blotting for the angiogenic molecules VEGF, VEGFR-2 and p-VEGFR-2 as well as
p-FAK, FAK, p-p38 and p38. GAPDH served as a loading control.
doi:10.1371/journal.pone.0020614.g005
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inhibited by p-MMP-2 treatment. Radiation therapy plays a role in
upregulating the expression of molecules such as VEGF, VEGFR,
and EGFR [37–39], all of which are considered key targets for novel
anti-cancer therapies [40,41]. Further, studies support a possible link
between MMP-2 and the potent angiogenic factor, VEGF. MMPs
may stimulate VEGF release from tumor cells either directly or by
activating factors involved in VEGF release or by mobilizing VEGF
from the extracellular compartments [42–44]. Thus, by decreasing
the availability of VEGF, MMP-2 downregulation efficiently blocked
radiation-enhanced angiogenesis in U-251 and U-87 cells in the
present study. Several studies demonstrated a marked increase in
VEGF secretion following irradiation of cancer cells [15]. Kaliski, et
al. [45] showed that irradiated melanoma cells displayed enhanced
invasivecapacitywithincreasedMMP-2expressionandsubsequently
induced VEGF protein secretion. Specific MMP-2 inhibition blocked
Figure 7. p-MMP-2 combined with radiation inhibits tumor growth in vivo. U-251 (1610
6) cells were injected intracerebrally into athymic
mice. After ten days, animals were separated into five groups and were treated on alternate days with intracerebral injections of p-SV or p-MMP-2 for
a total of 4 doses (60 mg per dose) and 2 doses of radiation (4 Gy per dose) as described in Materials and Methods. Six weeks after the experiment was
initiated, mice were euthanized with intracardiac perfusion of PBS, followed by formaldehyde. The brains were then removed. A, Six weeks after the
experiment was initiated, an intraperitonal injection of 2.5 mg D-luciferin sodium salt diluted in 50 mL of PBS was given, and animals were
photographed under the IVIS camera for fluorescent light emission. The brains were removed and fixed in 10% phosphate-buffered formaldehyde,
and the fixed tissue samples were then processed into paraffin blocks. Brain sections (5 mM thick) were stained with hematoxylin and eosin (H&E), and
photographed under a light microscope (46and 406). B, Every fifth or sixth brain section (5 mM thick) was stained with H&E solution, and the tumor
masses (H&E-stained) were manually traced on the microscope attached computer screen. Areas were calculated using Image Pro Discovery Program
software (Media Cybernetics, Inc., Silver Spring, MD). The total tumor volume was calculated as the summed area on all slices, multiplied by the slice
separation. Columns: mean of area of tumor portion of all mice in the group (n=8); bars: SD; *p,0.01, **p,0.001, significant difference from mock,
p-SV or irradiated controls.
doi:10.1371/journal.pone.0020614.g007
Figure 6. p-MMP-2 inhibits colony formation and induces apoptosis and activation of pro-apoptotic molecules in glioma cells.
A, Clonogenic assay was performed as described in Materials and Methods. The cells were cultured, and colonies larger than 50 cells were counted.
Columns: mean of triplicate experiments; bars: SD; *p,0.01, significant difference from radiation. B, U-251 and U-87 cells were transfected with mock,
p-SV or p-MMP-2, and irradiated as described earlier. After 24 h of radiation, cells were evaluated with the TUNEL assay according to manufacturer’s
instructions and photographed under fluorescent microscopy. Apoptosis was measured by counting the percentage of cells that showed DNA
staining in five different fields in each group. Columns: mean of triplicate experiments; bars: SD; *p,0.01, **p,0.001, significant difference from mock,
p-SV or irradiated controls. C, Equal amounts of protein from whole cell lysates of control and treated cells were analyzed by Western blotting using
caspase-specific primary antibodies. GAPDH served as a loading control.
doi:10.1371/journal.pone.0020614.g006
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vivo. Hovinga, et al. [46] showed that radiation-enhanced VEGF
secretion increased angiogenesis and decreased apoptosis, both
leading to GBM radioresistance. As a consequence of VEGF
signaling, many proteins are activated by VEGFR-2 via an unknown
mechanism; these proteins include Src, phosphoionisitide 3-kinase
(PI3K), focal adhesion kinase (FAK), and p38 mitogen activated
protein kinase (p38 MAPK). These downstream signal transduction
molecules propagate a signal leading to several different endothelial
cellular functions such as survival, permeability, migration, and
proliferation [47]. In the present study, concomitant with the
decrease in VEGF and VEGFR-2, p38 and FAK phosphorylation
were also downregulated, with a corresponding inhibition of tumor
cell migration and invasiveness. Radiation-enhanced VEGF has also
Figure 8. p-MMP-2 combined with radiation enhances apoptosis in vivo.A ,Immunohistochemical analysis of brain sections using anti-MMP-
2,anti-VEGF and anti-pFAK antibodies. Sections were photographed (606). Also shown is the negative control where the primary antibody was
replaced by non-specific IgG (insets). B, Tissue sections of mice were evaluated with the TUNEL assay according to manufacturer’s instructions and
photographed under fluorescent microscopy (606). For the negative control, samples were incubated with label solution (without terminal
transferase) instead of TUNEL reaction mixture (insets). C, siRNA against MMP-2 inhibits U251 tumor cell invasion in vivo. H&E staining was performed
according to standard protocol, and representative pictures of tumor sections from mock, pSV, p-MMP-2-treated mice are shown (206and 606).
D, Immunohistochemical analysis of brain sections using anti-human nuclei (HuNu) antibody, a histological marker for identification of human cells (a
specific human nuclear antigen). Entire brain sections were photographed (46; middle row); shown on the top row is a non-tumor region (406; top
row); and shown on the bottom row is tumor and non-tumor overlapping region (406; bottom row). Also shown is the negative control where the
primary antibody was replaced by non-specific IgG (inset).
doi:10.1371/journal.pone.0020614.g008
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tumor growth after irradiation. VEGF is reported to reduce apoptosis
after irradiation in human leukemia cells and in human and murine
mammary adenocarcinoma cells [48–50]. The simultaneous admin-
istration of p-MMP-2 with radiation opposed the anti-apoptotic
phenotype and led to cleavage/activation of the pro-apoptotic
molecules caspase 3, caspase 8 and caspase 9. Studies have shown
that virtually all glioma-derived cell lines exhibit resistance to
radiation and do not undergo radiation-induced primary apoptosis
[51,52]. In the present study, U-251 and U-87 cells demonstrated
very high levels of apoptosis as shown by TUNEL assay when
irradiated cells were concomitantly administered p-MMP-2. These
findings were further validated in vivo.I no u rin vivo studies, p-MMP-2
reduced tumor size by more than 80% compared to mock or pSV.
Although the tumor size in mice that received radiation treatment
alone did not increase significantly, the invasive nature of the tumor
did increase drastically. Tumor cells that manage to escape the lethal
effects of irradiation often adapt more aggressive properties,
proliferate more rapidly and display enhanced migratory, invasive
and angiogenic potential [53,54]. Further, sub-lethal doses of
radiation have a toxic effect on healthy tissues and may also result
in a more aggressive and malignant tumor due to the development of
resistant cancer cell sub-populations that have enhanced proliferative,
invasive and angiogenic properties [54]. Treatment with both p-
MMP-2 and radiation did reduce radiation-induced tumor cell
infiltration and tumor size by ,80% compared to mock and pSV
controls (Figs. 7A–B).
Radiation-enhanced expression as well as activation of the
MMP-2 proteolytic system elevate or modify the bioavailability of
several molecules that promote tumor progression [17–23].
Further, enhanced MMP-2 may increase tumor survival by
decreasing apoptosis, stimulating proliferation, and increasing
angiogenic and invasive potential [13–16]. Since the downregu-
lation of MMP-2 seems to cause the modulation of several other
molecules and pathways, MMP-2 siRNA is effective in modulating
radiation-enhanced molecules, invasiveness and altering signaling
pathways, thereby driving the cells through apoptosis.
It is worth noting that in all of our experiments, glioma cells that
were treated only with p-MMP-2 showed a significant downreg-
ulation of tumorigenic properties and were capable of acquiring an
apoptotic phenotype. This proves the anti-tumor efficacy of p-
MMP-2. Nevertheless, since radiotherapy is the standard treat-
ment for glioma and malignant glioma is one of the most
radioresistant tumor types, the administration of p-MMP-2 prior
to radiotherapy could be a potent adjuvant therapeutic approach
to improve the efficacy of radiotherapy for glioma. Adenoviral
vectors have been widely used both in cells and in vivo for the
delivery of MMP-2 siRNA [27–29]. Although they may be
capable of efficiently delivering the gene to the target cells,
adenovirus carries the risk of triggering an immune response,
which limits the length of time that the gene expression can be
maintained in the target cells. Plasmids, on the other hand, being
non-infectious and non-immunogenic, could be much safer and
provide stability of gene transfer [30]. The results of our study
demonstrated the efficacy of p-MMP-2 in inhibiting radiation-
enhanced tumor invasion and progression and suggest that it may
act as a potent adjuvant for radiotherapy in malignant glioma.
Materials and Methods
Ethics Statement
The Institutional Animal Care and Use Committee (IACUC) of
the University of Illinois College of Medicine at Peoria, Peoria, IL,
USA, approved all surgical interventions and post-operative
animal care. The consent was written and approved. The animal
protocol number is 858, dated May 27, 2009, and renewed on
April 27, 2010.
Cell cultures
Glioblastoma cell lines U-251 and U-87 obtained from
American Type Culture Collection (ATCC, Manassas, VA) were
grown in Dulbecco’s modified Eagle’s medium (DMEM). Cultures
were supplemented with 1% glutamine, 100 mg/mL streptomycin,
100 U/mL penicillin and 10% fetal calf serum (FCS) and
maintained in a humidified atmosphere containing 5% CO2 at
37uC.
Plasmid vector constructs, transient transfection, and
radiation treatment
The plasmid constructs carrying siRNA against MMP-2 (p-
MMP-2) and a scrambled MMP-2 sequence (p-SV) were designed
and constructed as previously described [27]. pcDNA3.0 (Invitro-
gen) with a CMV promoter was used for the construction of
vectors. The following siRNA sequences were cloned into the
pcDNA3.0: aacggacaaagagttggcagtatcgatactgccaactctttgtccgtt for
p-MMP-2 inverted repeat sequence and gcacggaggttgcaaagaa-
taatcgattattctttgcaacctccgtgc for p-SV inverted repeat sequence.
Annealed oligos were sequentially ligated to pcDNA3.0 at the Nhe
I site. Briefly, 150,000 cells were seeded in 6-cm diameter dishes
and grown in DMEM supplemented with 10% FCS. The cells
were transfected with mock (PBS), p-SV, or p-MMP-2. Transfec-
tions were performed using FuGENE HD transfection reagent
(Roche Applied Science, Indianapolis, IN) as per the manufac-
turer’s instructions. After 72 h of transfection, cells were irradiated
with a single dose of radiation (2, 4, 6, 8, 10 or 12 Gy). The RS
2000 Biological irradiator (Rad Source Technologies, Boca Raton,
FL) X-ray unit operated at 150 kv/50 mA was used for radiation
treatments. All experiments were performed 24 h after radiation.
Gelatin zymography
Cells were transfected with mock, p-SV or p-MMP-2 alone or in
combination with various single doses of radiation (2, 4, 6, 8, 10 or
12 Gy) to which cells were exposed 72 h after transfection.
Following radiation, cells were cultured for 24 h in serum-free
DMEM/F-12 medium. The serum-free conditioned medium was
collected and equal amounts of protein were used to determine
MMP-2 activity. Gelatin zymography was performed as previously
described [55].
Reverse transcription-PCR
Cells were transfected and irradiated as described above. Total
RNA was extracted using TRIZOL reagent (Life Technologies,
Rock-ville, MD) according to the manufacturer’s protocol. RT-
PCR was performed as described previously [27]. PCR products
were resolved on 2% agarose gels and were visualized by ethidium
bromide staining. To normalize for the amount of input RNA,
RT-PCR was performed with primers for GAPDH. We used the
following specific primers: MMP-2, forward 59-GTGCTGAAG-
GACACACTAAAGAAGA-39, and reverse 59-TTGCCATCCT-
TCTCAAAGTTGTAGG-39; GAPDH, forward 59-TGAAGGT-
CGGAGTCAACGGATTTGGT-39, and reverse 59-CATGTG-
GGCCATGAGGTCCACCAC-39. Images were generated by
Alpha Innotech Image Acquisition and Analysis Software.
Western blot analysis
U-251 and U-87 cells were transfected and irradiated as
described earlier. Equal amounts of total protein from cell lysates
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(pH 7.4), 150 mM/L NaCl, 1% IGEPAL, 1 mM/L EDTA,
0.25% sodium deoxycholate, 1 mM/L sodium fluoride, 1 mM/
L sodium orthovanadate, 0.5 mM/L PMSF, 10 mg/mL aprotinin,
10 mg/mL leupeptin] were separated by SDS–PAGE and
transferred to polyvinylidene difluoride membranes (Bio-Rad,
Hercules, CA). After blocking with 5% nonfat dry milk and 0.1%
Tween-20 in PBS, membranes were incubated with 1:1000
dilution of primary antibodies followed by incubation in HRP-
conjugated secondary antibodies. Membranes were developed
using the ECL system (Amersham Bioscience Corp., Piscataway,
NJ). Primary antibodies used in this study were: MMP-2, MMP-9,
VEGF, VEGFR-2, pVEGFR-2, pFAK, FAK, p-p38, total p38,
caspase 3, caspase 8, caspase 9, GAPDH (used as a loading
control), HRP conjugated secondary antibodies (Santa Cruz
Biotechnology, SantaCruz, CA).
Cell proliferation assay
Cell growth was assessed by MTT assay. U-251 and U-87 cells
(5610
3 cells per well) were grown in 96-well plates, transfected and
irradiated as described earlier. Proliferation rate was measured
24 h after treatment by adding 20 mL of MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) solution
(R&D Systems, Minneapolis, MN) to each well and further
incubating the plate for 1 h. Samples were read on a microplate
reader using test wavelength of 550 nm and reference wavelength
of 655 nm.
Immunofluorescence
U-251 and U-87 cells were cultured in 8-well chamber slides
(Nalge Nunc International, Naperville, IL) (10
4 cells per well),
transfected and irradiated as described earlier. After 24 h of
treatment, cells were fixed in 3% formaldehyde and incubated with
0.2%TritonX-100inPBS.Cellswere thenblocked with3%bovine
serum albumin (BSA)for1 h and incubated with mouseanti-MMP-
2 in 1% BSA in PBS (dilution 1:500). Cells were washed with PBS
and mouse fluorescein isothiocyanate (FITC)-conjugated secondary
antibody was added for 1 h. Finally, slides were washed with PBS,
mounted and examined under a fluorescent microscope connected
to an Olympus camera.
Spheroid migration assay
Cells (4610
4) were seeded in 96-well plates coated with 1%
agarose in PBS and cultured on a shaker at 100 rpm for 48 h.
After single spheroids formed, cells were transfected with mock, p-
SV or p-MMP-2 alone or in combination with various doses of
radiation as described earlier. Treated spheroids were placed in
the center of each well of vitronectin-coated 96-well plates and
were cultured at 37uC for 24 h in serum-free DMEM, after which
they were fixed and stained with Hema-3. The migration of cells
from the center of the spheroids to monolayers was measured
using a microscope calibrated with a stage and ocular micrometer.
We used Image Pro Discovery Program software to determine the
index of cell migration (Media Cybernetics, Inc., Silver Spring,
MD) as described previously [36].
Matrigel invasion assay
U-251 and U-87 cells were transfected and irradiated as
described earlier. Transwell inserts (ThinCertTM; Greiner Bio-
One, Monroe, NC) with 8 mm pores were coated with 200 mL
growth factor reduced Matrigel (Collaborative Research, Inc.,
Boston MA) at a concentration of 0.7 mg/mL in DMEM serum-
free medium for 3–4 h. 500 mL of cell suspension (5610
5 cells)
were added into wells in triplicate. Cells were allowed to invade
through the Matrigel for 24 h. Cells in the upper chamber were
removed by cotton swab. Cells adhered on the outer surface that
had invaded though the Matrigel were fixed, stained with Hema-3,
photographed and counted under a light microscope as previously
described [36].
In vitro angiogenesis assay
Conditioned medium-induced microtubule network formation
in vitro was determined. Cells were transfected and irradiated as
described earlier. Conditioned medium from U-251 and U-87
control and treated cells was collected and added to HMEC
(5610
4 per well) seeded the previous day in 96-well plates. HMEC
were incubated for 24 h and the formation of microtubule
networks was examined after fixing and staining the cells with
Hema-3. The angiogenic result was measured by counting the
relative branch points in each field for the different treatment
groups.
Clonogenic assay
U-251 and U-87 cells were transfected and irradiated as
described earlier. Cells were trypsinized and 200 cells were seeded
in 100-mm Petri dishes. On day 10 after irradiation, cells were
fixed in methanol and stained with Giemsa. Colonies (.50 cells)
were counted and survival fraction was calculated as number of
colonies divided by the number of plated cells.
TUNEL assay and apoptosis
U-251 and U-87 cells were grown in 8-well chamber slides,
transfected and irradiated as described earlier. Then, terminal
deoxynucleotidyl transferase biotin-dUTP nick end-labeling (TU-
NEL) assay was performed using an apoptosis detection kit (Roche
Applied Science, Indianapolis, IN) according to the manufactur-
er’s instructions. Briefly, cells were fixed with 3% paraformalde-
hyde and incubated with 0.2% Tween-20, 0.2% BSA in PBS for
15 min at room temperature. Cells were washed with PBS and
incubated with terminal deoxynucleotidyl transferase end-labeling
cocktail for 60 min. The reaction was stopped with Tris-borate
buffer, and cells were washed and incubated for 30 min in the
dark with avidin-FITC solution diluted in the provided blocking
buffer. Finally, cells were washed, mounted and photographed
under a fluorescent microscope. Apoptosis was measured as the
average percentage of positive nuclei per field for each treatment.
Animal studies
Experiments in nude mice were carried out according to the
protocol approved by the IACUC of this institution. U-251
glioblastoma cells stably transfected with a luciferin-expressing
plasmid were grown in serum-containing culture media. Cells
were trypsinized and resuspended in PBS. 10 mL( 1 610
6 cells) was
injected intracerebrally into nude mice. To detect tumor growth,
animals received an intraperitoneal injection of 2.5 mg of D-
luciferin sodium salt (Gold Biotechnology, St Louis, MO)
suspended in 50 mL of PBS, and tumor growth was monitored
using IVIS-200 Xenogen imaging system (Xenogen Corporation,
Alameda, CA). Tumors were allowed to grow for 10 days before
animals were separated into five treatment groups of eight mice
each. Two groups of animals were treated on alternate days with
intracerebral injections of p-SV or p-MMP-2 for a total of 4 doses
(60 mg per dose in 10 mL volume; flow rate ,1 mL/10 sec).
Between the first and the second injections and between the
second and the third injections, the animals that were adminis-
tered p-MMP-2 were also irradiated with a dose of 4 Gy each
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at 8 Gy. Only the tumor region was exposed to radiation while the
rest of the mouse body was covered with lead sheet. Control
animals were injected with PBS (mock) only. After 6 weeks and/or
when the control animals started showing symptoms, animals were
anesthetized and euthanized by intracardiac perfusion of PBS
followed by formaldehyde. The brains were removed, and fixed in
10% phosphate-buffered formaldehyde and the fixed tissue
samples were then processed into paraffin blocks. Every fifth or
sixth section (5 mm thick) was stained with hematoxylin-eosin
solution (H&E) and the tumor masses (H&E-stained) were
manually traced on the microscope attached to a computer. Areas
were calculated using Image Pro Discovery Program software
(Media Cybernetics, Inc., Silver Spring, MD). The total tumor
volume was calculated as the summed area on all slices, multiplied
by the slice separation [56], and normalized to the volume of
tumor in p-SV treated mice. For the immunohistochemical
experiments, brain sections were deparaffinized in xylene and
rehydrated through graded alcohol. Then, slides were incubated
with 0.1% Triton X-100, blocked with 3% BSA in PBS, and
incubated with anti-MMP-2, anti-VEGF, anti-pFAK (Santa Cruz
Biotechnology, SantaCruz, CA) or anti-human nuclei (HuNu)
antibody (Millipore, Temecula, CA) (1:10 dilution). After a rinse in
PBS, slides were incubated with HRP-conjugated secondary
antibody for 1 h at a dilution of 1:300, washed again with PBS
and incubated with 0.05% 3,30-diaminobenzidine as chromogen.
Finally, slides were counterstained with hematoxylin, mounted
and observed under a light microscope. Tissue sections were also
subject to TUNEL assay performed using an apoptosis detection
kit (Roche Applied Science, Indianapolis, IN) according to the
manufacturer’s instructions.
Statistical analysis
Data are presented as the arithmetic mean 6 standard
deviation (SD) of at least three independent experiments, each
performed at least in triplicate. Results were analyzed using a two-
tailed Student’s t-test to assess statistical significance. In the animal
experiments, the mean differences in tumor volumes were
compared among treatment groups using a one-way analysis of
variance (ANOVA). Statistical differences are presented at
probability levels of p,0.05, ,0.01 and ,0.001.
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